Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis

Alex M. Dickens et al.

Supplementary Material
**Supplementary Table 1.** Tandem MS analysis of endocannabinoids. Information on quantification and selective reaction monitoring (SRM) transitions for identification.

| Compound | Ionization | Ion Type | Retention Time | Internal Standard | SRM (amu)         | CE (eV) |
|----------|------------|----------|----------------|-------------------|------------------|--------|
| THC-COOH | Negative   | Quantifier | 1.23           | THC-COOH d9       | 343.400 → 245.100 | -32    |
| THC-COOH | Negative   | Qualifier  | 1.23           | THC-COOH d9       | 343.400 → 299.000 | -32    |
| PEA      | Positive   | Quantifier | 3.13           | AEA-d8            | 300.400 → 62.100  | 19     |
| PEA      | Positive   | Qualifier  | 3.13           | AEA-d8            | 300.400 → 283.100 | 19     |
| 1-AG     | Positive   | Quantifier | 3.24           | 2-AG d5           | 379.300 → 287.300 | 21     |
| 1-AG     | Positive   | Qualifier  | 3.24           | 2-AG d5           | 379.300 → 203.200 | 21     |
| 2-AG     | Positive   | Quantifier | 2.97           | 2-AG d5           | 379.300 → 287.300 | 21     |
| 2-AG     | Positive   | Qualifier  | 2.97           | 2-AG d5           | 379.300 → 203.200 | 21     |
| 2-AGe*   | Positive   | Quantifier | 3.23           | 2-AG d5           | 365.400 → 273.200 | 20     |
| 2-AGe*   | Positive   | Qualifier  | 3.23           | 2-AG d5           | 365.400 → 121.000 | 20     |
| NADA*    | Positive   | Quantifier | 2.69           | NADA d8           | 440.300 → 137.100 | 30     |
| NADA*    | Positive   | Qualifier  | 2.69           | NADA d8           | 440.300 → 154.100 | 30     |
| AEA      | Positive   | Quantifier | 2.26           | AEA-d8            | 348.300 → 62.100  | 32     |
| AEA      | Positive   | Qualifier  | 2.26           | AEA-d8            | 348.300 → 133.100 | 32     |
| OEA      | Positive   | Quantifier | 3.61           | AEA-d8            | 326.300 → 62.100  | 20     |
| OEA      | Positive   | Qualifier  | 3.61           | AEA-d8            | 326.300 → 309.300 | 20     |
| AA       | Negative   | Quantifier | 4.48           | AA-d8             | 303.300 → 259.100 | -20    |
| AA       | Negative   | Qualifier  | 4.48           | AA-d8             | 303.300 → 58.900  | -20    |
| SEA      | Positive   | Quantifier | 5.92           | AEA-d8            | 328.400 → 62.100  | 23     |
| SEA      | Positive   | Qualifier  | 5.92           | AEA-d8            | 328.400 → 311.400 | 23     |

*Analyte below limit of detection in study samples.*
Supplementary Figure 1. CB1R availability in the posterior cingulate cortex (PCC) versus the circulating levels of endocannabinoids in Turku and London cohorts. (a) Scatter plots fitted with a linear regression model of CB1R availability in the posterior cingulate cortex (PCC) versus the log-transformed circulating levels of endocannabinoids from the Turku cohort. (b) Scatter plots fitted with a linear regression model of CB1R availability in the posterior cingulate cortex (PCC) versus the log-transformed circulating levels of endocannabinoids from the London cohort. The line shows the linear model for each dataset.